Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1197-1201

  Gharwan, Helen ^a   Truica, Cristina I ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

Bortezomib; Kappa; Lambda; Light chain deposition disease; Renal failure

Indexed keywords

ALISKIREN; BENCE JONES PROTEIN; BETA 2 MICROGLOBULIN; BORTEZOMIB; CALCIUM; CD38 ANTIGEN; CIPROFLOXACIN; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EZETIMIBE PLUS SIMVASTATIN; HYDROCHLOROTHIAZIDE; METFORMIN; METRONIDAZOLE; NAPROXEN; SYNDECAN 1; TELMISARTAN; THALIDOMIDE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN KAPPA CHAIN; PYRAZINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CHILL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIAPHORESIS; DISEASE ASSOCIATION; FEVER; FLOW CYTOMETRY; GLOMERULUS FILTRATION RATE; HEADACHE; HYPERCALCEMIA; HYPERTENSION; IMMUNOPEROXIDASE STAINING; KIDNEY BIOPSY; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY MEDULLA; LIGHT CHAIN DEPOSITION DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA AND VOMITING; PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN ELECTROPHORESIS; PROTEINURIA; TREATMENT RESPONSE; ULTRASOUND; UREA NITROGEN BLOOD LEVEL; CASE REPORT; DIFFERENTIAL DIAGNOSIS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROGNOSIS; REMISSION;

ACUTE KIDNEY INJURY; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; REMISSION INDUCTION;

EID: 84864002302     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9938-4     Document Type: Article

References (18)

1. Randall RE, Williamson WC Jr, Mullinax F, Tung MY, Still WJ. Manifestations of systemic light chain deposition. Am J Med. 1976;69:703-10.
2. Seymour AE, Thompson AJ, Smith PS, Woodroffe AJ, Clarkson AR. Kappa light chain glomerulosclerosis in multiple myeloma. Am J Pathol. 1980;101:557-80.
3. Pozzi C, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42:1154-63.
4. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol. 2001;12:1558-65.
5. Gokden N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol. 2008; 32(1):17-24.
6. Solomon A. Bence-Jones proteins and light chains of immunoglobulins. N Engl J Med. 1976;294:91-8.
7. Strober W, Waldmann TA. The role of the kidney in the metabolism of plasma proteins. Nephron. 1974;13:35-66.
8. Melmed GM, Fenves AZ, Stone MJ. Urinary findings in renal light chain-derived amyloidosis and light chain deposition disease. Clin Lymphoma Myeloma. 2009;9(3):234-8.
9. Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006;1:1342-50.
10. Zhu L, Herrera GA, Murphy-Ullrich JE, Huang ZQ, Sanders PW. Pathogenesis of glomerulosclerosis in light chain deposition disease. role for transforming growth factor-beta. Am J Pathol. 1995;147:375-85.
11. Hootkins R, Fenvez AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol. 1989;32:75-8.
12. Stratta P, Lazzarich E, Canavese C, Bozzolo C, Monga G. Ciprofloxacin crystal nephropathy. Am J Kidney Dis. 2007;50: 330-5.
13. Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA. Longterm follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis. 1992;20:34-41.
14. Royer B. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int. 2004;65:642-8.
15. Lorenz EC. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant. 2008;23:2052-7.
16. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood. 2007;109:2604-6.
17. Hideshima T. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-47.
18. Gilmore TD. Multiple myeloma: lusting for NF-kappaB. Cancer Cell. 2007;12:95-7.